brochure
Frontage offers an impressive suite of services to take lead candidate drugs to the IND stage. With Experimur’s acquisition, Frontage now has significantly expanded our range of services, supporting customers’ drug-development programs beyond IND and into NDA-enabling toxicology studies. Frontage has exceptional bioanalytical supporting capabilities for small molecules, large molecules, and biomarkers.